Screening for pharmacological chaperones in Fabry disease
Authors:
- 1 July 2007
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 359 (1) , 168-173
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Neurological Disorders and Stroke
- Amicus Therapeutics
This publication has 20 references indexed in Scilit:
- Enzyme Replacement for Lysosomal DiseasesAnnual Review of Medicine, 2006
- Storage solutions: treating lysosomal disorders of the brainNature Reviews Neuroscience, 2005
- Detection of ?-galactosidase a mutations causing fabry disease by denaturing high performance liquid chromatographyHuman Mutation, 2005
- A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorderThe FASEB Journal, 2005
- Transgenic mouse expressing human mutant α-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2004
- Pharmacological Enhancement of β-Hexosaminidase Activity in Fibroblasts from Adult Tay-Sachs and Sandhoff PatientsJournal of Biological Chemistry, 2004
- A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activityTrends in Pharmacological Sciences, 2003
- Improvement in Cardiac Function in the Cardiac Variant of Fabry's Disease with Galactose-Infusion TherapyNew England Journal of Medicine, 2001
- Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's diseaseClinica Chimica Acta, 1981
- Neuropathological and biochemical studies in Fabry's diseaseActa Neuropathologica, 1974